NLS Pharmaceutics Ltd. (NLSP)
- Previous Close
0.1325 - Open
0.1325 - Bid --
- Ask --
- Day's Range
0.1325 - 0.1398 - 52 Week Range
0.1310 - 1.5500 - Volume
71,300 - Avg. Volume
564,492 - Market Cap (intraday)
5.749M - Beta (5Y Monthly) -0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
nlspharma.comRecent News: NLSP
Performance Overview: NLSP
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NLSP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NLSP
Valuation Measures
Market Cap
5.75M
Enterprise Value
4.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-414.25%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.47M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.65M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.95M